PGDx, MolecularMD Ink Co-Marketing Deal

Oct 25, 2013

|

NEW YORK (GenomeWeb News) – Personal Genome Diagnostics today announced a deal with MolecularMD to market personalized medicine services to oncology researchers and drug developers.

The deal combines PGDx's expertise in next-generation sequencing-based cancer biomarker discovery with MolecularMD's capabilities in developing and validating cancer companion diagnostics, PGDx said. Under the agreement's terms, the two companies will co-market each other's services to drug manufacturers and biotechnology customers.

Further financial terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Try the Other Version

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

You Do Your Way

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

CRISPR Discussions

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

This Week in Science

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sep

27

Featured Webinar

Large-scale, Prospective Tumor and Normal Sequence to Accelerate Biomarker Discovery and Guide Clinical Care

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep

28

Featured Webinar

Clinical Utility of Comprehensive and Fast Genomic Interpretation

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.

Main menu